

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Yues International Holdings Group Limited**

**樂氏國際控股集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1529)**

### **SUPPLEMENTAL ANNOUNCEMENT**

#### **IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024**

#### **AND**

#### **CHANGE IN USE OF PROCEEDS**

#### **FURTHER INFORMATION IN RELATION TO THE 2024 ANNUAL REPORT**

Reference is made to the annual report for the year ended 31 December 2024 of Yues International Holdings Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) published on 28 April 2025 (“**2024 Annual Report**”). Unless otherwise defined herein, capitalised terms used in this section shall have the same meanings as those defined in the 2024 Annual Report.

In addition to the information provided in the 2024 Annual Report, the Board would like to provide the following supplemental information to the shareholders of the Company regarding the Previous Share Option Scheme and the New Share Option Scheme.

Pursuant to the terms of the New Share Option Scheme, the eligible participants (the “**Eligible Participants**”) include (i) the director(s) and employee(s) (whether full-time or part time but excludes a former employee of the Group unless such former employee otherwise qualifies as an Eligible Participant) of any member of the Group (including persons who are granted options under the New Share Option Scheme as inducement to enter into employment contracts with any member of the Group) (the “**Employee Participants**”); (ii) directors and employees (whether full time or part time but excludes any former employee unless such former employee otherwise qualifies as an Eligible Participant) of the holding companies, fellow subsidiaries or associated companies of the Company (the “**Related Entity Participants**”); and (iii) person(s) who provide services to any member of the Group on a continuing or recurring basis in its ordinary and usual course of business which are in the interests of the long term growth of the Group, which include any contractor, supplier, agent, consultant, adviser and/or business partner to any area of business or business development of the Group, but excluding any placing agents or financial advisers providing advisory services for fundraising, mergers or acquisitions, and

other professional services provider such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity (the “**Service Providers**”).

Details of the options granted to the grantees under the Previous Share Option Scheme and movements in such holdings during the year ended 31 December 2024 were as follows:

| Categories of participants <i>(Note)</i> | Date of grant | Vesting period | Exercisable period            | Exercise price<br>(HK\$) | Number of share options    |                                 |                              |                                 |                              |
|--|---------------|----------------|-------------------------------|--------------------------|----------------------------|---------------------------------|------------------------------|---------------------------------|------------------------------|
|  |               |                |                               |                          | As at<br>1 January<br>2024 | Exercised<br>during<br>the Year | Lapsed<br>during<br>the Year | Cancelled<br>during<br>the Year | As at<br>31 December<br>2024 |
| <b>Directors</b>                         |               |                |                               |                          |                            |                                 |                              |                                 |                              |
| Mr. Li Jianxin                           | 1 June 2020   | Nil            | 1 June 2020 to<br>31 May 2030 | 0.188                    | 800,000                    | —                               | —                            | (800,000)                       | —                            |
| Mr. Li Jianming                          | 1 June 2020   | Nil            | 1 June 2020 to<br>31 May 2030 | 0.188                    | 800,000                    | —                               | —                            | (800,000)                       | —                            |
| Dr. Wan Ho Yuen<br>Terence               | 1 June 2020   | Nil            | 1 June 2020 to<br>31 May 2030 | 0.188                    | 800,000                    | —                               | (800,000)                    | —                               | —                            |
| Dr. Wu Ka Chee Davy                      | 1 June 2020   | Nil            | 1 June 2020 to<br>31 May 2030 | 0.188                    | 800,000                    | —                               | (800,000)                    | —                               | —                            |
| Mr. Shao Wei                             | 1 June 2020   | Nil            | 1 June 2020 to<br>31 May 2030 | 0.188                    | 800,000                    | —                               | (800,000)                    | —                               | —                            |
| Ms. Lin Jianfang                         | 1 June 2020   | Nil            | 1 June 2020 to<br>31 May 2030 | 0.188                    | 8,000,000                  | —                               | —                            | (8,000,000)                     | —                            |
| <b>Employees</b>                         | 1 June 2020   | Nil            | 1 June 2020 to<br>31 May 2030 | 0.188                    | 57,000,000                 | —                               | —                            | (57,000,000)                    | —                            |

*Note:* The categories of participants represented the position of grantees as at the date of grant.

## CHANGE IN USE OF PROCEEDS

Reference is made to the announcement of the Company dated 25 July 2025 in relation to change in use of proceeds (“**Announcement**”). In addition to the information provided in the Announcement, the Board would like to provide the following supplemental information to the shareholders of the Company regarding the use of proceeds. Unless otherwise defined herein, capitalised terms used in this section shall have the same meanings as those defined in the Announcement.

The Company plans to reallocate approximately HK\$20 million of the Unutilised Net Proceeds to support the development of the Chinese medicine business, and expects to fully utilise this amount by 31 December 2026. The remaining Unutilised Net Proceeds will be applied to general working capital and are also expected to be fully utilised by 31 December 2026.

The Board also wishes to provide additional information regarding the reason for the Proposed Change. On 8 July 2025, the Group, through an indirectly wholly-owned subsidiary of the Company, entered into a share transfer agreement to acquire 100% equity interest in Bozhou Lelaohao Medical Co., Ltd.\* (亳州樂老號醫藥有限公司), a company holding a Pharmaceutical Operation Permit (藥品經營許可證) and primarily engaged in the wholesale and distribution of pharmaceutical products. Further details of the acquisition were disclosed in the Company's announcement dated 8 July 2025.

The Proposed Change is made in the context of the Group's latest strategic priorities and market opportunities, with the intention to leverage this acquisition as a gateway to further explore upstream and downstream opportunities in the pharmaceutical value chain and expand its overall value creation capabilities. The reallocated proceeds will primarily be used for supply chain development and pharmaceutical product procurement in support of the Group's Chinese medicine business.

As at the date of this announcement, the Company has no plan or intention, nor has it entered into any negotiation, agreement, arrangement or understanding (whether formal or informal, express or implied) to dispose of or downsize its existing business or to acquire any new business, other than as disclosed above.

By order of the Board  
**Yues International Holdings Group Limited**  
**Le Kang**  
*Chairman*

Hong Kong, 8 August 2025

*As at the date of this announcement, the Board consists of four executive Directors, Mr. Le Kang, Mr. Li Zhigang, Mr. Li Jiahao and Ms. Liu Ping, and three independent non-executive Directors, Mr. Lau Wai Piu Patrick, Dr. Wang Yi and Mr. Zhang Yao.*